Nexell Therapeutics Recognized for Contributions Made to Cell Therapy Industry
IRVINE, Calif.--(BUSINESS WIRE)--Jan. 12, 2000--Nexell Therapeutics Inc. (Nasdaq:NEXL) announced today that the company has been awarded Frost & Sullivan's 1999 Marketing Strategy Award, one of the Market Engineering Leadership Awards presented to companies that made a positive contribution to the growing U.S. cell therapy market. The award was announced December 20, 1999 in a press release issued by Frost & Sullivan.
"Nexell's superior technology and indisputable patent protection coupled with an aggressive marketing strategy are helping the company make significant strides in the area of stem cell transplantation in the United States," said Viji Subramanyam, an industry analyst with Frost & Sullivan. "Nexell is in a unique position to translate these competitive advantages into sustainable market leadership as the cell therapy field continues to grow in size and
complexity."
In the Marketing Strategy Award citation, Frost & Sullivan also noted that Nexell had successfully consolidated the U.S. stem cell selection market, following the exit of CellPro, by systematically phasing out that company's Ceprate instruments and replacing them with the Isolex(R) 300i Magnetic Cell Selection System.
"We are pleased that our contribution to the cell technology field has been recognized," said William McIntosh, President and COO of Nexell Therapeutics. "Our unique technology, aggressive research program and business plan are enabling us to move rapidly toward our clinical and financial goals."
Frost & Sullivan
Frost & Sullivan is an international marketing consulting and training company that monitors the healthcare industry for market trends, market measures, and strategies. More information is available at www.frost.com.
Nexell Therapeutics Inc.
Located in Irvine, California, Nexell Therapeutics Inc. (Nasdaq:NEXL) is a cell therapy company whose mission is to put the power of the cell into the hands of healers. Nexell is developing and marketing innovative ex vivo cell therapies and in vitro diagnostics for cancer, autoimmune, metabolic and genetic diseases. Nexell's lead product, the Isolex(R) 300i Magnetic Cell Selection System, is the only FDA approved device commercially available for
the selection of hematopoietic stem cells and the removal of tumor cells from autologous peripheral blood as a component of aggressive cancer treatment. In addition, Nexell markets the Cytonex(TM) ICC Staining Kit and an extensive line of cell therapy preparation, storage and expansion products including the Cryocyte(TM), SteriCell(R) and Lifecell(R) brands.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect either Company's actual results and could cause results to differ from those contained in the forward-looking statements
contained herein are: the timely commencement and success of either Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in either Company's periodic reports on Form 10-K and 10-Q, and any
prospectus describing either Company's securities.
NOTE TO INVESTORS AND EDITORS: Nexell Therapeutics Inc. press releases are available on the Internet through www.nexellinc.com and through Business Wire's web site at businesswire.com. The releases are also available at no charge through Business Wire's fax-on-demand service at 800-411-8792.
CONTACT:
Nexell Therapeutics Inc., Irvine
Tad Heitmann, 949/470-6516
KEYWORD: CALIFORNIA
|
